Ubicación: Global + English
Global Global Algérie Français Algeria English Angola Português Angola English Argentina Español Argentina English Australia English Austria Deutsch Austria English Azerbaijan English Azerbaijan Русский Bahrain English Bangladesh English Belgium English Belgium Français Belgium Nederlands Brazil Português Brazil English Bulgaria български Bulgaria English Cameroon English Cameroon Français Canada English Canada Français Chile Español Chile English China 中文 China 日本語 China English Colombia Español Colombia English Croatia English Czech Republic Čeština Czech Republic English Denmark English Djibouti English Ecuador Español Ecuador English Egypt English Estonia English Ethiopia English Finland Suomi Finland English France Français France English Georgia English Georgia Русский Germany Deutsch Germany English Ghana English Greece Ελληνικά Greece English Guatemala Español Guatemala English Hong Kong, China English Hong Kong, China 中文 Hungary Magyar Hungary English India English Indonesia English Iraq English Ireland English Italy Italiano Italy English Ivory Coast Français Ivory Coast English Japan 日本語 Japan English Jordan English Kazakhstan Русский Kazakhstan English Kenya English Kuwait English Kyrgyzstan Русский Kyrgyzstan English Latvia English Lithuania English Malaysia English Mauritius English Mauritius français (Maurice) Mexico Español Mexico English Moldova Română Moldova English Mongolia English Morocco English Morocco Français Mozambique Português Mozambique English Netherlands Nederlands Netherlands English New Zealand English Nigeria English Norway English Oman English Pakistan English Paraguay Español Paraguay English Peru Español Peru English Philippines English Poland Polski Poland English Portugal Português Portugal English Qatar English Republic of Korea 한국어 Republic of Korea English Romania Română Romania English Saudi Arabia English Serbia Српски Serbia English Singapore English Slovakia English Slovenia English South Africa English Spain English Spain Español Sri Lanka English Sweden English Switzerland Deutsch Switzerland Français Switzerland Italiano Switzerland English Tanzania English Thailand ไทย Thailand English Togo English Togo Français Tunisia English Tunisia Français Türkiye Türkçe Türkiye English Turkmenistan Русский Turkmenistan English Ukraine Українська Ukraine English United Arab Emirates English United Kingdom English Uruguay Español Uruguay English USA English Uzbekistan English Uzbekistan Русский Vietnam Tiếng Việt Vietnam English

Z0-1 (Zonula Occludens-1) immunohistochemistry analysis is a specialized laboratory technique used to detect the localization and expression of this key tight junction scaffolding protein in tissue sections. This experiment provides essential insights into epithelial and endothelial barrier integrity, making it invaluable for research in inflammatory diseases, vascular permeability, and tumor biology. This article presents a comprehensive technical overview of Z0-1 protein immunohistochemistry, covering sample requirements, testing protocols, quantification methods, and practical applications.

Z0-1 Protein Immunohistochemistry Analysis Experiment

Technical Overview

Z0-1 (Zonula Occludens-1), also known as tight junction protein 1 (TJP1), is a 220–225 kDa peripheral membrane phosphoprotein belonging to the membrane-associated guanylate kinase (MAGUK) family. It is encoded by the TJP1 gene and serves as a critical scaffolding molecule at tight junctions, linking transmembrane proteins such as claudins, occludin, and junctional adhesion molecules (JAMs) to the actin cytoskeleton.

Immunohistochemistry (IHC) analysis of Z0-1 utilizes highly specific antibodies to visualize the distribution and expression intensity of the protein in tissue sections. Under physiological conditions, Z0-1 exhibits a continuous, linear membranous staining pattern along intercellular junctions of epithelial and endothelial cells. Disruption, fragmentation, or cytoplasmic redistribution of Z0-1 staining is widely recognized as a hallmark of barrier dysfunction and increased paracellular permeability.

  • Target protein: Z0-1 / TJP1 (Zonula Occludens-1)
  • Molecular weight: approximately 220–225 kDa
  • Subcellular localization: cytoplasmic side of tight junctions, cell-cell borders
  • Detection principle: antigen-antibody specific binding with enzyme-chromogen visualization
  • Common detection systems: SP (streptavidin-peroxidase) method or polymer-based two-step detection

Testing Samples

Paraffin-Embedded Tissue Sections

Formalin-fixed, paraffin-embedded (FFPE) tissue is the most commonly used sample type for Z0-1 immunohistochemistry. Tissues should be fixed in 4% paraformaldehyde or 10% neutral buffered formalin for 24–48 hours to preserve antigenicity and junctional morphology. Sections are cut at 3–5 μm thickness and mounted on adhesive-coated slides to prevent detachment during heat-induced antigen retrieval.

Frozen Tissue Sections

Fresh tissue snap-frozen in OCT embedding compound and sectioned at 6–8 μm is recommended when antigen epitopes are sensitive to fixation or when co-staining with fluorescent markers is required. Frozen sections generally preserve protein conformation better and may yield stronger signals for certain antibody clones.

Cell Samples

Cultured epithelial or endothelial cells can be analyzed using cytospin preparations, cell blocks, or coverslip-grown monolayers. Confluent monolayers grown on chamber slides are particularly suitable for evaluating the formation of continuous Z0-1 junctional rings in vitro.

Recommended Tissue Types

  • Gastrointestinal tract: intestinal mucosa for barrier function and inflammatory bowel disease studies
  • Brain tissue: microvessels and choroid plexus for blood-brain barrier integrity assessment
  • Kidney: glomeruli and tubules for podocyte injury and nephropathy research
  • Liver: bile canaliculi and sinusoidal endothelium for cholestasis and injury models
  • Lung: alveolar epithelium and pulmonary microvasculature for acute lung injury studies
  • Tumor tissues: for evaluating tight junction loss during invasion and epithelial-mesenchymal transition (EMT)

Testing Items

The Z0-1 immunohistochemistry experiment typically includes the following analytical components:

  • Qualitative detection: positive or negative expression of Z0-1 protein in target tissues
  • Subcellular localization: membranous (junctional), cytoplasmic, or nuclear staining pattern
  • Distribution morphology: continuous linear staining versus discontinuous, fragmented, or punctate patterns
  • Semi-quantitative scoring: immunoreactive score (IRS) calculated as staining intensity (0–3) multiplied by positive cell percentage (0–4)
  • Quantitative image analysis: measurement of integrated optical density (IOD), mean optical density (MOD), and relative expression area using Image-Pro Plus or ImageJ software
  • Comparative analysis: statistical comparison between experimental groups and controls
  • Optional multiplex staining: co-localization with occludin, claudins, or EMT markers such as E-cadherin and vimentin

Testing Methods

The standard chromogenic immunohistochemistry protocol for Z0-1 detection is performed as follows:

  • Sample preparation: tissue fixation, paraffin embedding, sectioning at 3–5 μm, and slide baking at 60°C for 1–2 hours
  • Deparaffinization and rehydration: xylene graded series followed by ethanol gradient hydration
  • Antigen retrieval: heat-induced epitope retrieval in citrate buffer (pH 6.0) or EDTA buffer (pH 8.0–9.0) using a pressure cooker or microwave
  • Blocking: incubation with 3% hydrogen peroxide to quench endogenous peroxidase activity, followed by normal serum blocking to reduce nonspecific binding
  • Primary antibody incubation: rabbit anti-Z0-1 monoclonal or polyclonal antibody, typically diluted 1:100–1:500, incubated overnight at 4°C
  • Secondary antibody and detection: biotinylated secondary antibody followed by HRP-conjugated streptavidin, or a polymer-based HRP detection system
  • Chromogenic reaction: DAB substrate development monitored under a microscope, producing brown staining at antigen sites
  • Counterstaining and mounting: hematoxylin nuclear counterstain, dehydration, clearing, and permanent mounting
  • Microscopic evaluation and image acquisition: documentation under standardized illumination conditions for quantitative analysis

Quality control measures are essential for reliable results. Positive control tissue (such as small intestine or kidney) confirms antibody performance, while a negative control using PBS in place of the primary antibody verifies staining specificity. Interpretation should focus on junctional localization, as diffuse cytoplasmic background may indicate nonspecific staining.

Applications

Z0-1 immunohistochemistry analysis is widely applied across multiple research and diagnostic fields:

  • Intestinal barrier research: evaluation of mucosal integrity in inflammatory bowel disease, necrotizing enterocolitis, and leaky gut models
  • Neurovascular studies: assessment of blood-brain barrier disruption in stroke, trauma, sepsis, and neurodegenerative disease models
  • Renal pathology: analysis of podocyte foot process effacement and tubular barrier damage in diabetic nephropathy and glomerulonephritis
  • Hepatobiliary research: examination of bile canalicular tight junction remodeling in cholestasis and drug-induced liver injury
  • Pulmonary medicine: investigation of alveolar-capillary barrier breakdown in acute lung injury and ARDS
  • Oncology: study of tight junction loss during tumor progression, EMT, invasion, and metastasis
  • Pharmacology and toxicology: efficacy and safety evaluation of barrier-protective agents, tight junction modulators, and permeability-enhancing drugs
  • Ischemia-reperfusion and sepsis research: quantification of vascular endothelial barrier damage in organ injury models

FAQ

Why is Z0-1 staining weak or absent in my samples?

Common causes include delayed fixation leading to antigen degradation, over-fixation masking epitopes, suboptimal antigen retrieval conditions, or excessive primary antibody dilution. Optimization of retrieval buffer pH, retrieval duration, and antibody working concentration is recommended.

How should discontinuous or fragmented Z0-1 staining be interpreted?

A discontinuous, fragmented, or relocated cytoplasmic staining pattern generally indicates structural disruption of tight junctions and impaired barrier function. Quantitative comparison of continuous junction length or staining area between groups provides objective evidence of barrier damage.

What are the sample submission requirements?

Fresh tissue should be delivered rapidly in cold transport medium, fixed tissue can be shipped in fixative solution at room temperature, and FFPE blocks or pre-cut sections should be shipped at ambient temperature with protection from moisture. A minimum tissue volume of approximately 100 mg or at least 5 serial sections is recommended.

How is the staining quantified?

Semi-quantitative IRS scoring combines staining intensity and positive cell percentage, while digital image analysis measures integrated and mean optical density values. At least 5–10 random high-power fields per sample should be analyzed to ensure statistical reliability.

What is the difference between IHC and immunofluorescence for Z0-1?

Chromogenic IHC is durable, compatible with archived FFPE material, and easily interpreted under standard brightfield microscopy. Immunofluorescence offers higher sensitivity for subcellular junctional detail and enables multiplex co-localization, but requires fluorescence microscopy and is less stable during long-term storage.

What is the typical turnaround time?

Standard processing, staining, imaging, and analysis generally require 5–10 working days after sample receipt, depending on sample volume and whether additional optimization or multiplex staining is requested.